

Powering the future of genetic medicines with precision delivery



nature

"Seven technologies to watch in 2022"

Why ReCode?

- · A rare company whose innovations are poised to fundamentally shift an entire class of medicine
- · Pre-IPO and backed by blue chip investors
- · Inclusive culture with curious, kind, and passionate people
- · Comprehensive benefits and flexible work arrangements
- · Pioneering disease-modifying mRNA therapeutics that address the underlying cause of genetic diseases, including primary ciliary dyskinesia and cystic fibrosis

Pipeline

	Indication	Modality	Target	Delivery	Discovery	Preclinical	Phase 1/2
LUNG	Primary Ciliary Dyskinesia (PC		DNAI1 CCDC39/40	Inhaled Inhaled			
		mRNA	PCD gene 3	Inhaled			
	Cystic Fibrosis (CF)	mRNA	CFTR	Inhaled			
		Gene correction	CFTR	Inhaled			
	Other	mRNA	Undisclosed	Inhaled / IV			
		Gene correction	Undisclosed	Inhaled / IV			
LIVER	Various	Multiple	Undisclosed	IV			
CNS	Various	Multiple	Undisclosed	Intrathecal			

An experienced leadership team

with substantial genetic medicines, orphan drug and technology development expertise



SHEHNAAZ SULIMAN, M.D., M.B.A., M.Phil Chief Executive Officer



DAVID J. LOCKHART, Ph.D. President & Chief Scientific Officer



JOHN G. MATTHEWS, MBBS, MRCP, Ph.D. **Chief Medical Officer**

























